Tetradecylthioacetic Acid for Health & Longevity - Quick Reference Sheet

Tetradecylthioacetic Acid for Health & Longevity

Created on 09/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Tetradecylthioacetic acid is a lab-made fatty acid, sold online as a research chemical and fat-loss supplement, that pushes the liver and muscles to burn more ordinary fat. A few small, month-long human studies suggest a modest drop in harmful cholesterol and blood fats in people with abnormal blood fats; healthy volunteers showed no change within a week. Safety knowledge ends at four weeks; long-term risks are largely unknown. (Full Review)

Protocol

Clinical research protocol
1,000 mg orally once daily
For 28 days, as used in the diabetes, HIV and psoriasis trials
Dose-finding range
200, 600 and 1,000 mg/day
Tested for 7 days in healthy volunteers; only 1,000 mg/day has efficacy data
Time of day
No trial specified timing
With a fat-containing meal mirrors normal fatty-acid absorption; morning versus evening dosing is untested
Time to effect
Blood lipids
4 weeks
Lipid changes appeared after 4 weeks at 1 g/day; 7 days was too short to show any change
Lipid non-response
8 weeks
If lipids have not moved by 8 weeks, the compound is unlikely to help that person
Blood pressure
7–28 days
Fell slightly in two small, short uncontrolled human studies

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Children and adolescents under 18 years
  • Active liver disease (Child-Pugh class B or C cirrhosis, or ALT or AST above 3× the upper limit of normal)
  • Severe kidney impairment (eGFR below 30 mL/min/1.73 m²)
  • Heart failure NYHA class III–IV or heart attack within the past 90 days
  • Symptomatic gallstone disease
  • Already taking two or more other PPAR-activating drugs or supplements (e.g., fenofibrate, pioglitazone, oleoylethanolamide)
Key Interactions
  • Fibrates (fenofibrate, gemfibrozil, bezafibrate): Caution
  • Statins (cholesterol-lowering drugs: atorvastatin, rosuvastatin, simvastatin): Monitor
  • Thiazolidinediones (PPARγ-activating diabetes drugs: pioglitazone, rosiglitazone): Caution
  • Glucose-lowering drugs (metformin, insulin, sulfonylureas such as glipizide): Monitor
  • Antipsychotics (olanzapine, clozapine): Caution
  • HIV protease inhibitors (antiviral drugs: lopinavir, ritonavir): Monitor
  • Tamoxifen: Monitor
  • Over-the-counter niacin (nicotinic acid, vitamin B3 at lipid doses): Caution
  • Over-the-counter orlistat (a fat-absorption blocker): Monitor
  • Fish oil (EPA, eicosapentaenoic acid, and DHA): Monitor, potentially favorable
  • Oleoylethanolamide (a PPARα-activating supplement often stacked with TTA): Caution
  • Red yeast rice and berberine (additive LDL-lowering supplements): Caution
  • L-carnitine: Monitor
  • Ketogenic diet or prolonged fasting: Monitor
  • Heavy alcohol use: Caution

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild short-term adverse events
  • Speculative: Lower omega-3 blood levels; reduced heart efficiency; liver enlargement and rodent liver tumors; liver fat accumulation; fibrate-type kidney, muscle and gallbladder effects; cardiovascular harm seen with related drugs; growth-signal activation counter to longevity goals; altered B-vitamin markers

Monitoring

Marker Target Why
LDL cholesterol <100 mg/dL (<2.6 mmol/L) Main efficacy marker
ApoB <80 mg/dL Counts artery-clogging particles
Triglycerides <100 mg/dL (<1.1 mmol/L) Efficacy marker
HDL cholesterol ≥50 mg/dL Lipid balance
ALT / AST ALT <25 U/L; AST <25 U/L Liver safety
Creatinine / eGFR eGFR >90 mL/min/1.73 m² Kidney safety
CK No established functional target; track change from own baseline Muscle safety
Omega-3 index ≥8% Tracks omega-3 depletion
Fasting glucose / HbA1c 70–90 mg/dL; HbA1c <5.4% Metabolic effect
hs-CRP <1.0 mg/L Systemic inflammation
Methylmalonic acid <0.27 µmol/L B12 status check

Cadence: Baseline before starting (after a 10–12-hour fast), 4–6 weeks after starting, then every 3 months while use continues, and once 4–8 weeks after stopping

Qualitative Assessment

  • Energy levels and exercise tolerance, especially any new breathlessness
  • Digestive comfort after dosing
  • Waist circumference and body weight trend
  • Muscle aches or weakness
  • Skin changes in people with psoriasis